How does CMA-mediated TET3 degradation mechanistically silence the cGAS-STING pathway?

OPEN

The study shows CMA degrades TET3 leading to cGAS-STING silencing and immune escape, but the mechanistic link between TET3 loss and pathway suppression is unclear. This gap limits understanding of how autophagy controls tumor immunity in brain cancers. Gap type: unexplained_observation Source paper: Targeting chaperone-mediated autophagy inhibits properties of glioblastoma stem cells and restores anti-tumor immunity. (2026, Nature communications, PMID:41390755)

Priority: 0.80 Domain: neuroinflammation Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: How does CMA-mediated TET3 degradation mechanistically silence the cGAS-STING pathway? is a 0.8 priority gap in neuroinflammation. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

How does CMA-mediated TET3 degradation mechanistically silence the cGAS-STING pathway? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (35)

STINGSenescenceCGASSTINGAPOPTOSISSTINGGPX4STINGSTINGIFN
▸ Show 30 more

associated with (2)

STINGAlsSTINGCGAS-STING

encodes (1)

STINGSTING

inhibits (5)

STINGAlsINFLAMMATIONSTINGSTINGInflammationSTINGCGAS-STINGCGASSTING

regulates (4)

STINGAlsSTINGInnate ImmunityCGASSTINGSTINGAutophagy

targets (1)

CGASSTING

therapeutic target (2)

STINGInflammationSTINGCGAS-STING
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps